Free tool
FAERS Monitor: Rolvedon
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761148 or its brand name (Rolvedon, Eflapegrastim-Xnst). Reports on generic versions are filed under their own applications.
Reports
30
Serious
16
53% of reports
Hospitalization
10
Death reported
4
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- white blood cell count increased4
- asthenia3
- diarrhoea3
- leukocytosis3
- off label use3
- abdominal pain2
- accidental exposure to product2
- bone pain2
- constipation2
- fatigue2
- febrile neutropenia2
- nausea2
- pancytopenia2
- thrombocytopenia2
- vomiting2
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2022 | 2 |
| 2023 | 2 |
| 2024 | 13 |
| 2025 | 10 |
| 2026 | 3 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,129 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| leukocytosisSignal | 3 | 116.2 | 39.7 | 237 |
| white blood cell count increasedSignal | 4 | 73.1 | 29.4 | 217 |
| pancytopenia | 2 | 25.1 | 6.6 | 25 |
| bone pain | 2 | 23.9 | 6.3 | 24 |
| febrile neutropenia | 2 | 21.1 | 5.5 | 21 |
| accidental exposure to product | 2 | 13.6 | 3.6 | 13 |
| thrombocytopenia | 2 | 12.5 | 3.3 | 11 |
| constipation | 2 | 6.4 | 1.7 | 5 |
| abdominal pain | 2 | 6.0 | 1.6 | 4 |
| astheniaSignal | 3 | 5.6 | 1.9 | 7 |
| diarrhoea | 3 | 3.3 | 1.1 | 3 |
| vomiting | 2 | 3.0 | 0.8 | 1 |
| off label use | 3 | 2.4 | 0.8 | 1 |
| fatigue | 2 | 1.8 | 0.5 | 0 |
| nausea | 2 | 1.8 | 0.5 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.